We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Dolichol Biomarker Evaluated for Congenital Disorders of Glycosylation

By LabMedica International staff writers
Posted on 14 Aug 2020
Print article
The AB MDS SCIEX API4000 tandem mass spectrometer (Photo courtesy of SCIEX).
The AB MDS SCIEX API4000 tandem mass spectrometer (Photo courtesy of SCIEX).
A congenital disorder of glycosylation (CDG; previously called carbohydrate-deficient glycoprotein syndrome) is one of several rare inborn errors of metabolism in which glycosylation of a variety of tissue proteins and/or lipids is deficient or defective.

CDG often cause serious, sometimes fatal, malfunction of several different organ systems (especially the nervous system, muscles, and intestines) in affected infants. Dolichol is a membrane lipid which carries monosaccharides and glycans for N-linked protein glycosylation occurring in the endoplasmic reticulum.

Scientists from the Charles University and General University Hospital (Prague, Czech Republic) analyzed urine samples from 75 controls, six patients with CDG ((NUS1-CDG, SRD5A3-CDG, two with PMM2-CDG, PGM1-CDG, DPAGT1-CDG), and 43 patients with suspicion of CDG. Furthermore, tissue homogenates (frontal cortex, skeletal muscle, heart and liver) from two NUS1-CDG patients and two controls (at the age 0–5 years) were also analyzed. The dolichol ratio determination was established as a non-invasive screening method and evaluated through a screening for rare CDG syndromes.

The urine and tissue samples were processed and homogenized with a 4710 Series Ultrasonic Homogenizer, (Cole Parmer, Vernon Hills, IL, USA). The dolichols (Dol) were analyzed by using the AB MDS SCIEX API4000 tandem mass spectrometer (Applied Biosystems, Foster City, CA, USA) coupled with Agilent 1290 Infinity UPLC System (Agilent Technologies, Santa Clara, CA, USA).

The dolichol 18 to dolichol 19 (Dol18/Dol19) ratio biomarker was compared in urine samples with different CDGs to evaluate its use for identifying these disorders. The investigators reported that in the control group, a significant correlation between the ratio of Dol18/Dol19 and age was found in urine. They established a reference range for Dol18/Dol19 from the urine samples. The ratio of Dol18/Dol19 was significantly higher in both urine and tissue samples from patients with mutation in NUS1 in comparison to controls.

The authors concluded that their results on test samples show a novel diagnostic option for patients with rare congenital disorders of glycosylation, especially for those with pathological mutations in NUS1, who cannot be detected by usual screening methods. The study was published in the August, 2020 issue of the journal Clinica Chimica Acta.


Related Links:

Charles University and General University Hospital
Cole Parmer
Applied Biosystems
Agilent Technologies
Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.